Abstract 2013P
Background
Cytotoxic T lymphocyte antigen 4 (CTLA4) and T cell immunoreceptor with Ig and ITIM domains (TIGIT) immune checkpoints are expressed on tumor-infiltrated immune cells (TILs) in SCLC and represent promising immunotherapy targets. We aimed to assess the frequency and clinical relevance of CTLA4 and TIGIT expression in the peripheral blood (PB) of patients with SCLC.
Methods
PB was obtained from 90 SCLC patients prior to first-line treatment (chemotherapy=61; combination of chemotherapy/anti-PD-L1 inhibitors: n=29). Peripheral blood mononuclear cell (PBMC) cytospins were stained for CTLA4/TIGIT/dapi. CTLA4 and TIGIT protein expression was individually assessed on 1000 intact PBMCs via fluorescence microscopy; the mean % value was used to define high expression of each marker.
Results
CTLA4 and TIGIT were expressed on PBMCs in 95.6% and 100% of patients, respectively, with a mean percentage of positive PBMCs per patient: 27.8% and 34.5%, respectively. Their expression was not associated with clinicopathological parameters or survival outcomes in the entire patient population. However, separate analysis of the chemoimmunotherapy group (n=29 extensive-stage SCLC patients) revealed that high versus low expression of CTLA4 and/or TIGIT was a marker for increased progression-free survival and overall survival (median PFS: 8.7 vs 4.7 months, p=0.000; median OS: 13.9 vs 5.9 months, p=0.038; respectively by Kaplan Meier analysis); on the contrary, no correlation was shown for patients treated with chemotherapy only (median PFS: 6.2 vs 7.9 months, p=0.877 and median OS: 11.6 vs 15.1, p=0.142). Moreover, among extensive-stage patients with high expression of CTLA4 and/or TIGIT on PBMCs (n=45 patients), the administration of chemoimmunotherapy was associated with improved survival rates as compared to those receiving chemotherapy only (median OS: 14 vs 7.8 months, p=0.005).
Conclusions
CTLA4 and TIGIT are frequently expressed on PBMCs of SCLC patients and are correlated with significant clinical benefit from the addition of anti-PD-L1 inhibitors to first-line chemotherapy. Their role as immunotherapy biomarkers in SCLC merits further investigation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1997P - A study of sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-disease small cell lung cancer
Presenter: Zhe-Hai Wang
Session: Poster session 05
1999P - IMreal Cohort 4: Third interim analysis of efficacy and safety in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) receiving atezolizumab plus carboplatin and etoposide (atezo + CE) as first-line (1L) therapy under real-world conditions (RWCs)
Presenter: Sanjay Popat
Session: Poster session 05
2000P - Efficacy and safety of thoracic radiotherapy after first-line immunotherapy in extensive stage small cell lung cancer: A multi-center retrospective study
Presenter: Jiake Wu
Session: Poster session 05
2001P - Consolidative thoracic radiotherapy of extensive-stage small cell lung cancer in the era of chemoimmunotherapy: A retrospective analysis concerning patients from southern Italy
Presenter: Vito Longo
Session: Poster session 05
2002P - A multicentre study assessing the real-world effectiveness of first-line chemotherapy plus immunotherapy in extensive-stage small cell lung cancer (ES-SCLC) patients
Presenter: Marie Porte
Session: Poster session 05
2003P - Consolidative intrathoracic radiotherapy during maintenance first-line immunotherapy in extensive stage small cell lung cancer (ES-SCLC): A retrospective multicenter analysis of safety and efficacy
Presenter: Alessio Bruni
Session: Poster session 05
2004P - PD-L1 Inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real-world evidence
Presenter: Litang Huang
Session: Poster session 05
2005P - Anlotinib combined with chemotherapy in the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC): A real-world study
Presenter: Fangfang Gao
Session: Poster session 05
2006P - Immune activation effect and survival of different irradiated sites in ES-SCLC patients treated with radioimmunotherapy: A real-world analysis
Presenter: Min Wu
Session: Poster session 05